Pharmacotherapies in Dupuytren Disease: Current and Novel Strategies.

[1]  A. Gaffo,et al.  Emerging strategies for treating gout. , 2022, Current opinion in pharmacology.

[2]  S. Bellusci,et al.  A role for metformin in the treatment of Dupuytren disease? , 2022, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[3]  M. Feldmann,et al.  Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial , 2022, The Lancet Rheumatology.

[4]  G. Kasting,et al.  Pirfenidone as a potential antifibrotic injectable for Dupuytren’s disease , 2022, Pharmaceutical development and technology.

[5]  A. Burlui,et al.  Targeting Systemic Sclerosis from Pathogenic Mechanisms to Clinical Manifestations: Why IL-6? , 2022, Biomedicines.

[6]  R. Moseley,et al.  Myofibroblasts: Function, Formation, and Scope of Molecular Therapies for Skin Fibrosis , 2021, Biomolecules.

[7]  L. Dahlin,et al.  Metabolic factors and the risk of Dupuytren’s disease: data from 30,000 individuals followed for over 20 years , 2021, Scientific Reports.

[8]  Andrea C. Kakouri,et al.  Fibrotic expression profile analysis reveals repurposed drugs with potential anti-fibrotic mode of action , 2021, PloS one.

[9]  P. Carlier,et al.  Non-invasive assessment of skeletal muscle fibrosis in mice using nuclear magnetic resonance imaging and ultrasound shear wave elastography , 2021, Scientific Reports.

[10]  S. Zhang,et al.  Silencing COX-2 blocks PDK1/TRAF4-induced AKT activation to inhibit fibrogenesis during skeletal muscle atrophy , 2020, Redox biology.

[11]  J. Carter,et al.  Inhibition of COX‐2 Pathway as a Potential Prophylaxis Against Arthrofibrogenesis in a Rabbit Model of Joint Contracture , 2019, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[12]  M. Glassberg.  Overview of idiopathic pulmonary fibrosis, evidence-based guidelines, and recent developments in the treatment landscape. , 2019, The American journal of managed care.

[13]  Chaoming Zhou,et al.  Investigating the effects of Pirfenidone on TGF-β1 stimulated non-SMAD signaling pathways in Dupuytren’s disease -derived fibroblasts , 2019, BMC Musculoskeletal Disorders.

[14]  Lifei Guo,et al.  Dupuytren’s Contracture: An Evidence Based Review , 2018, Annals of plastic surgery.

[15]  P. Werker,et al.  Alternative and Adjunctive Treatments for Dupuytren Disease. , 2018, Hand clinics.

[16]  L. Hurst,et al.  Development of Collagenase Treatment for Dupuytren Disease. , 2018, Hand clinics.

[17]  A. Zhang,et al.  The Basic Science of Dupuytren Disease. , 2018, Hand clinics.

[18]  L. Dahlin,et al.  Three-year recurrence of Dupuytren’s contracture after needle fasciotomy and collagenase injection: a two-centre randomized controlled trial , 2018, The Journal of hand surgery, European volume.

[19]  M. Feldmann,et al.  Anti-Tumour Necrosis Factor Therapy for Dupuytren's Disease: A Randomised Dose Response Proof of Concept Phase 2a Clinical Trial , 2018, EBioMedicine.

[20]  Jaipaul Singh,et al.  Angiotensin receptors in Dupuytren’s disease: a target for pharmacological treatment? , 2017, Journal of plastic surgery and hand surgery.

[21]  A. Gray,et al.  Study protocol: A multi-centre, double blind, randomised, placebo-controlled, parallel group, phase II trial (RIDD) to determine the efficacy of intra-nodular injection of anti-TNF to control disease progression in early Dupuytren’s disease, with an embedded dose response study. , 2017, Wellcome open research.

[22]  J. Lange,et al.  Injectable Collagenase Versus Percutaneous Needle Fasciotomy for Dupuytren Contracture in Proximal Interphalangeal Joints: A Randomized Controlled Trial. , 2017, The Journal of hand surgery.

[23]  A. Maderal,et al.  Keloids and Hypertrophic Scars: Pathophysiology, Classification, and Treatment , 2017, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[24]  S. Hansen,et al.  Evidence-Based Medicine: Options for Dupuytren’s Contracture Incise, Excise, and Dissolve , 2017, Plastic and reconstructive surgery.

[25]  Chaoming Zhou,et al.  Anti-fibrotic action of pirfenidone in Dupuytren’s disease-derived fibroblasts , 2016, BMC Musculoskeletal Disorders.

[26]  J. Chan,et al.  Systematic review of non-surgical treatments for early dupuytren’s disease , 2016, BMC Musculoskeletal Disorders.

[27]  R. Amirfeyz,et al.  Critical Angles of Deformity in Dupuytren's Contracture of the Little and Ring Fingers. , 2015, Hand surgery : an international journal devoted to hand and upper limb surgery and related research : journal of the Asia-Pacific Federation of Societies for Surgery of the Hand.

[28]  A. Suzuki,et al.  Treatment response in the PIVENS trial is associated with decreased hedgehog pathway activity , 2015, Hepatology.

[29]  L. D. Ketchum.  The Rationale for Treating the Nodule in Dupuytren’s Disease , 2014, Plastic and reconstructive surgery. Global open.

[30]  S. Hovius,et al.  Minimally invasive options in Dupuytren's contracture: aponeurotomy, enzymes, stretching, and fat grafting. , 2014, Plastic and reconstructive surgery.

[31]  R. Sciot,et al.  High-dosage tamoxifen as neoadjuvant treatment in minimally invasive surgery for Dupuytren disease in patients with a strong predisposition toward fibrosis: a randomized controlled trial. , 2014, The Journal of bone and joint surgery. American volume.

[32]  H. Parlakpınar,et al.  Protective and Therapeutic Effect of Molsidomine on Bleomycin-Induced Lung Fibrosis in Rats , 2014, Inflammation.

[33]  Seung Hoon Lee,et al.  Metformin Reduces TGF-β1–Induced Extracellular Matrix Production in Nasal Polyp–Derived Fibroblasts , 2014, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[34]  E. Mercken,et al.  Metformin improves healthspan and lifespan in mice , 2013, Nature Communications.

[35]  J. Rosenbloom,et al.  Strategies for anti-fibrotic therapies. , 2013, Biochimica et biophysica acta.

[36]  M. Feldmann,et al.  Unraveling the signaling pathways promoting fibrosis in Dupuytren's disease reveals TNF as a therapeutic target , 2013, Proceedings of the National Academy of Sciences.

[37]  R. Goodacre,et al.  Dupuytren's disease metabolite analyses reveals alterations following initial short-term fibroblast culturing. , 2012, Molecular bioSystems.

[38]  C. McMillan,et al.  Steroid injection and needle aponeurotomy for Dupuytren contracture: a randomized, controlled study. , 2012, The Journal of hand surgery.

[39]  M. Freshwater.  What were the adverse events for Dupuytren’s patients treated with Xiaflex who had contractures less than 20°? , 2012, Hand.

[40]  P. Kloen,et al.  Concurrent inhibition of TGF-β and mitogen driven signaling cascades in Dupuytren's disease - non-surgical treatment strategies from a signaling point of view. , 2012, Medical hypotheses.

[41]  W. LaFramboise,et al.  Fibroblasts from phenotypically normal palmar fascia exhibit molecular profiles highly similar to fibroblasts from active disease in Dupuytren's Contracture , 2012, BMC Medical Genomics.

[42]  E. Ziv,et al.  Clinical and biomarker predictors of side effects from tamoxifen , 2012, Breast Cancer Research and Treatment.

[43]  Luca Richeldi,et al.  Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. , 2011, The New England journal of medicine.

[44]  P. Kloen,et al.  Elevated transforming growth factor β and mitogen-activated protein kinase pathways mediate fibrotic traits of Dupuytren's disease fibroblasts , 2011, Fibrogenesis & tissue repair.

[45]  S. Sahn,et al.  Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials , 2011, The Lancet.

[46]  Xiaolei Zhou,et al.  Prevalence, incidence, and treatments of Dupuytren’s disease in the United States: results from a population-based study , 2010, Hand.

[47]  Ardeshir Bayat,et al.  Scientific understanding and clinical management of Dupuytren disease , 2010, Nature Reviews Rheumatology.

[48]  J. Nanchahal,et al.  Post‐transcriptional regulation of α‐smooth muscle actin determines the contractile phenotype of Dupuytren's nodular cells , 2010, Journal of cellular physiology.

[49]  J. Rajfer,et al.  Treatment of Peyronie's disease with PDE5 inhibitors: an antifibrotic strategy , 2010, Nature Reviews Urology.

[50]  A. Bayat,et al.  Differential Gene Expression Analysis of Subcutaneous Fat, Fascia, and Skin Overlying a Dupuytren’s Disease Nodule in Comparison to Control Tissue , 2009, Hand.

[51]  I. Stella,et al.  The Effects of Angiotensin-Converting Enzyme Inhibitors on the Fibrous Envelope around Mammary Implants , 2007, Plastic and reconstructive surgery.

[52]  A. Hatzelmann,et al.  Inhibition of TGF-beta induced lung fibroblast to myofibroblast conversion by phosphodiesterase inhibiting drugs and activators of soluble guanylyl cyclase. , 2007, European journal of pharmacology.

[53]  K L McGeoch,et al.  An Assessment of the Effects of Exposure to Vibration, Smoking, Alcohol and Diabetes on the Prevalence of Dupuytren’s Disease in 97,537 Miners , 2007, The Journal of hand surgery, European volume.

[54]  M. Gotway,et al.  Challenges in pulmonary fibrosis · 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias , 2007, Thorax.

[55]  B. Hinz.  Formation and function of the myofibroblast during tissue repair. , 2007, The Journal of investigative dermatology.

[56]  M. Ferrini,et al.  Effects of long‐term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie's disease , 2006, BJU international.

[57]  S. Dooley,et al.  N-Acetyl-L-Cysteine abrogates fibrogenic properties of fibroblasts isolated from Dupuytren's disease by blunting TGF-β signalling , 2006, Journal of cellular and molecular medicine.

[58]  J. Rabinowitz,et al.  Lipid composition and de novo lipid biosynthesis of human palmar fat in Dupuytren's disease , 1983, Lipids.

[59]  A. Gressner,et al.  N-acetyl-L-cysteine suppresses TGF-beta signaling at distinct molecular steps: the biochemical and biological efficacy of a multifunctional, antifibrotic drug. , 2005, Biochemical pharmacology.

[60]  R. Tse,et al.  Enhanced Dupuytren's disease fibroblast populated collagen lattice contraction is independent of endogenous active TGF-β2 , 2004, BMC musculoskeletal disorders.

[61]  Ling Yu,et al.  Combining TGF-beta inhibition and angiotensin II blockade results in enhanced antifibrotic effect. , 2004, Kidney international.

[62]  T. Sørensen,et al.  A prospective study linked both alcohol and tobacco to Dupuytren's disease. , 2004, Journal of clinical epidemiology.

[63]  A. Grobbelaar,et al.  A Prospective Randomised Clinical Trial of the Intra-Operative Use of 5-Fluorouracil on the Outcome of Dupuytren’s Disease , 2004, Journal of hand surgery.

[64]  H. Kosmehl,et al.  TGFβ and bFGF synthesis and localization in Dupuytren's disease (nodular palmar fibromatosis) relative to cellular activity, myofibroblast phenotype and oncofetal variants of fibronectin , 2004, The Histochemical Journal.

[65]  Mitchell R. Smith.  Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance , 2003, Oncogene.

[66]  A. Grobbelaar,et al.  The Different Characteristics of Dupuytren’s Disease Fibroblasts Derived from Either Nodule or Cord: Expression of α-Smooth Muscle Actin and the Response to Stimulation by TGF-β1 , 2003, Journal of hand surgery.

[67]  George Bou-Gharios,et al.  Effect of nitric oxide on the differentiation of fibroblasts into myofibroblasts in the Peyronie's fibrotic plaque and in its rat model. , 2002, Nitric oxide : biology and chemistry.

[68]  J. Reilly,et al.  The Effect of Steroids on Dupuytren’s Disease: Role of Programmed Cell Death , 2002, Journal of hand surgery.

[69]  M. Ferrini,et al.  Antifibrotic role of inducible nitric oxide synthase. , 2002, Nitric oxide : biology and chemistry.

[70]  B. Hinz,et al.  Myofibroblasts and mechano-regulation of connective tissue remodelling , 2002, Nature Reviews Molecular Cell Biology.

[71]  Francis Ko,et al.  Tamoxifen decreases fibroblast function and downregulates TGF(beta2) in dupuytren's affected palmar fascia. , 2002, The Journal of surgical research.

[72]  G. Gabbiani,et al.  Focal adhesion features during myofibroblastic differentiation are controlled by intracellular and extracellular factors. , 2001, Journal of cell science.

[73]  T. Husby,et al.  Acute postoperative swelling after hand surgery: an exploratory, double-blind, randomised study with paracetamol, naproxen, and placebo. , 2001, Scandinavian journal of plastic and reconstructive surgery and hand surgery.

[74]  L. D. Ketchum,et al.  The injection of nodules of Dupuytren's disease with triamcinolone acetonide. , 2000, The Journal of hand surgery.

[75]  R. Arngrímsson,et al.  Epidemiology of Dupuytren's disease: clinical, serological, and social assessment. The Reykjavik Study. , 2000, Journal of clinical epidemiology.

[76]  N. Davies,et al.  Clinical Pharmacokinetics and Pharmacodynamics of Celecoxib , 2000, Clinical pharmacokinetics.

[77]  P. Smith,et al.  The effect of 5-fluorouracil on Dupuytren fibroblast proliferation and differentiation. , 2000, Chirurgie de la main.

[78]  A. Ghahary,et al.  The effect of interferon-α2b on an in vitro model of Dupuytren's contracture , 1999 .

[79]  B. Cochran,et al.  Activation of the JAK-STAT pathway by reactive oxygen species. , 1998, American journal of physiology. Cell physiology.

[80]  M. Longaker,et al.  Tamoxifen Downregulates TGF-β Production in Keloid Fibroblasts , 1998 .

[81]  P. Burge,et al.  Smoking, alcohol and the risk of Dupuytren's contracture. , 1997, The Journal of bone and joint surgery. British volume.

[82]  P. Brenner,et al.  [Expression of various monoclonal antibodies in nodules and band stage in Dupuytren's disease]. , 1996, Handchirurgie, Mikrochirurgie, plastische Chirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Handchirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Mikrochirurgie der Peripheren Nerven und Gefasse : Organ der V....

[83]  G. Rayan,et al.  Pharmacologic regulation of Dupuytren's fibroblast contraction in vitro. , 1996, The Journal of hand surgery.

[84]  G. Liss,et al.  Can Dupuytren's contracture be work-related?: review of the evidence. , 1996, American journal of industrial medicine.

[85]  L. Hurst,et al.  The role of transforming growth factor beta in Dupuytren's disease. , 1996, The Journal of hand surgery.

[86]  K. Burridge,et al.  Focal adhesions, contractility, and signaling. , 1996, Annual review of cell and developmental biology.

[87]  T. Lue,et al.  Is colchicine effective in Peyronie's disease? A pilot study. , 1994, Urology.

[88]  A. Desmoulière,et al.  Effect of gamma-interferon on the clinical and biologic evolution of hypertrophic scars and Dupuytren's disease: an open pilot study. , 1994, Plastic and reconstructive surgery.

[89]  A. Jellema,et al.  The response of burn scars to intralesional verapamil. Report of five cases. , 1994, Archives of surgery.

[90]  P. Timmermans,et al.  Angiotensin II receptors and angiotensin II receptor antagonists. , 1993, Pharmacological reviews.

[91]  S. Ralston,et al.  Abnormal growth factor and cytokine expression in Dupuytren's contracture. , 1993, Journal of clinical pathology.

[92]  B. Nilsson,et al.  Prevalence of Dupuytren’s Contracture and its Correlation with Degenerative Changes of the Hands and Feet and with Criteria of General Health , 1993, Journal of hand surgery.

[93]  P. Maher,et al.  Basic fibroblast growth factor in cells derived from Dupuytren's contracture: synthesis, presence, and implications for treatment of the disease. , 1992, The Journal of hand surgery.

[94]  S. Baron,et al.  The interferons. Mechanisms of action and clinical applications. , 1991, JAMA.

[95]  C. Haaksma,et al.  Extracellular matrix-cytoskeletal connections at the surface of the specialized contractile fibroblast (myofibroblast) in Dupuytren disease. , 1987, The Journal of bone and joint surgery. American volume.

[96]  J. D. Spencer,et al.  Antibodies to collagen types I-VI in Dupuytren's contracture. , 1986, Journal of hand surgery.

[97]  R. Clark,et al.  In vivo co-distribution of fibronectin and actin fibers in granulation tissue: immunofluorescence and electron microscope studies of the fibronexus at the myofibroblast surface , 1984, The Journal of cell biology.

[98]  J. Heathcote,et al.  Diabetes mellitus in the aetiology of Dupuytren's disease. , 1984, The Journal of bone and joint surgery. British volume.

[99]  E. Menzel,et al.  Collagen Types and Anticollagen-Antibodies in Dupuytren's Disease , 1979, The Hand.

[100]  D. Kershenobich,et al.  Colchicine and the treatment of liver cirrhosis. , 1973, Lancet.

[101]  R. Diegelmann,et al.  Inhibition of collagen secretion from bone and cultured fibroblasts by microtubular disruptive drugs. , 1972, Proceedings of the National Academy of Sciences of the United States of America.

[102]  L. D. Ketchum,et al.  The Degradation of Mature Collagen: A Laboratory Study , 1967, Plastic and reconstructive surgery.

[103]  J V LUCK,et al.  Dupuytren's contracture; a new concept of the pathogenesis correlated with surgical management. , 1959, The Journal of bone and joint surgery. American volume.

[104]  L. Zachariae,et al.  Hydrocortisone acetate in the treatment of Dupuytren's contraction and allied conditions. , 1955, Acta chirurgica Scandinavica.

[105]  R. Weissenbach,et al.  [Treatment of Dupuytren's disease by local injections of hydrocortisone]. , 1953, Revue du rhumatisme et des maladies osteo-articulaires.

[106]  H. J. Richards.  Dupuytren's Contracture Treated with Vitamin E , 1952, British medical journal.

[107]  C. L. Steinberg.  Tocopherols in treatment of primary fibrositis; including Dupuytren's contracture, periarthritis of the shoulders, and Peyronie's disease. , 1951, A.M.A. archives of surgery.

[108]  G. R. Thomson.  Treatment of Dupuytren's Contracture with Vitamin E , 1949, British medical journal.